Tactical buy for an oversold rebound: price (3.08) is sitting just above key support (S1 ~3.04) with momentum selling pressure easing.
Options positioning is notably bullish (low put/call), suggesting traders are leaning upside despite elevated volatility.
Not a “fundamentals-first” buy: latest quarter showed revenue growth but sharp profitability deterioration; treat as a short-term trade rather than a long-term conviction entry.
Execution focus (impatient entry): buy here only while holding above ~3.04; upside levels to watch are ~3.28 (pivot) then ~3.53 (R1).
Technical Analysis
Trend/momentum: MACD histogram is negative (-0.0791) but contracting, implying bearish momentum is weakening (possible bottoming behavior).
RSI: RSI(6) at 28.11 indicates near-oversold conditions, supportive of a bounce setup.
Moving averages: converging MAs point to consolidation and a potential trend inflection rather than a strong ongoing uptrend.
Key levels: Support S1=3.04 (immediate) then S2=2.889; Resistance pivot=3.284 then R1=3.529 (next upside targets).
Pattern-based forward bias: similar-pattern stats suggest modest near-term chop (next week slightly negative) but a better 1-month drift (+4.98%).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Open interest put/call ratio at 0.25 is bullish (calls dominate), and today’s volume put/call is 0.0 (calls only).
Activity: today’s volume (52) is ~3.2x the 30-day average, indicating a pick-up in attention.
Volatility: 30D IV ~264.57% vs historical vol ~82.66% (very elevated). This supports “trader/speculative” conditions and can amplify both rebounds and drawdowns.
OI composition: call OI 14,026 vs put OI 3,450 reinforces upside positioning bias.
Technical Summary
Sell
4
Buy
8
Positive Catalysts
Technical setup favors a mean-reversion bounce: near-oversold RSI with price pressing support.
Analyst stance remains constructive with a Buy rating and raised target (latest noted PT $4.50).
Cost structure commentary from analyst: operating expenses lower in absence of Checkpoint (supports a cleaner story if sustained).
Neutral/Negative Catalysts
Institutional/insider flow signals are neutral (no strong “smart money” confirmation recently).
Financial Performance
Latest quarter: 2025/Q3.
Growth: Revenue increased to $17.631M (+20.52% YoY), a clear top-line positive.
Profitability: Net income fell to $3.675M (-124.43% YoY) and EPS dropped to $0.11 (-114.47% YoY), showing earnings pressure despite revenue growth.
Margins: Gross margin decreased to 61.32% (-3.99% YoY), indicating some erosion in profitability/efficiency.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Alliance Global (2025-11-19) reiterated Buy and raised price target to $4.50 from $4.00 after Q3 results.
Wall Street pro view: improving/leaner operating expense profile is a positive and the raised PT signals confidence in upside.
Wall Street con view: earnings and margin compression (despite revenue growth) is the key counterweight and likely the main reason the stock remains technically weak.
Influential trading check: No recent congress trading data available; hedge fund and insider trading trends are neutral (no notable accumulation/distribution signals).
Wall Street analysts forecast FBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBIO is 10.75 USD with a low forecast of 4.5 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBIO is 10.75 USD with a low forecast of 4.5 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.930
Low
4.5
Averages
10.75
High
17
Current: 2.930
Low
4.5
Averages
10.75
High
17
Alliance Global
Scott Henry
Buy
maintain
$4
AI Analysis
2025-11-19
Reason
Alliance Global
Scott Henry
Price Target
$4
AI Analysis
2025-11-19
maintain
Buy
Reason
Alliance Global analyst Scott Henry raised the firm's price target on Fortress Biotech to $4.50 from $4 and keeps a Buy rating on the shares following the Q3 report. The company's operating expenses are lower now in the absence of Checkpoint, the analyst tells investors in a research note.
H.C. Wainwright
Joseph Pantginis
Buy
downgrade
$26 -> $17
2025-08-21
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$26 -> $17
2025-08-21
downgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Fortress Biotech to $17 from $26 and keeps a Buy rating on the shares. The firm updated the company's model.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FBIO
